Revisiting the cost-effectiveness of omalizumab

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 62, Issue 12, 2007, Pages 1469-

  Campbell, J D ^a   Spackman, D E ^a   Sullivan, S D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OMALIZUMAB; PLACEBO;

ALLERGIC ASTHMA; CAUSE OF DEATH; COST EFFECTIVENESS ANALYSIS; DISEASE EXACERBATION; DRUG COST; HUMAN; LETTER; MORTALITY; PRIORITY JOURNAL; TREATMENT RESPONSE;

ANTI-ASTHMATIC AGENTS; ANTIBODIES, MONOCLONAL; ASTHMA; COST-BENEFIT ANALYSIS; DRUG COSTS; HUMANS; MODELS, ECONOMIC;

EID: 35748983798     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2007.01391.x     Document Type: Letter

References (4)

1. Brown R, Turk F, Dale P, Bousquet J. Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma. Allergy 2007 62 : 149 153.
2. Novartis Pharmaceutical Canada Inc. Prescribing Information Xolair. 2005 Available from: http://www.novartis.ca/downloads/en/products/xolair_scrip_e.pdf ; accessed 21 February 2007.
3. Humbert M, Beasley R, Ayres J, Slavin R, Hebert J, Bousquet J et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005 60 : 309 316.
4. Lowhagen O, Ekstrom L, Holmberg S, Wennerblom B, Rosenfeldt M. Experience of an emergency mobile asthma treatment programme. Resuscitation 1997 35 : 243 247.